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Introduction
Fish consumption is associated with cardiovascular disease (CVD) risk reduction in both observational and clinical intervention trials [1] . Fatty fish, such as salmon, tuna, herring, and mackerel are rich sources of omega-3 polyunsaturated fatty acids (n-3 PUFAs) which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which mediate the cardio-protective effects of fish [2] . It is commonly assumed that fish consumption is probably good for human health, especially because it provides high amounts of n-3 PUFAs, which lower triglycerides and, consequently, CVD [3] . In most previous experimental studies, which have investigated the effects of long-chain n-3 PUFAs on CVD risk, the doses of these fatty acids exceeded the amounts usually found in the diet. However, significant vascular benefits from modest fish consumption have been observed. In a prospective study, Yamagishi observed an inverse association between fish and n-3 PUFA consumption and the risks of mortality from heart failure (HF) and CVD [4] . The reduction in mortality associated with fish consumption is due to the positive effects on a number of cardiovascular risk factors. Fatty fish consumption can potentially modify both traditional and well-established markers, such as blood pressure, lipids and glucose; and novel markers such as adiponectin, leptin and inflammatory factors. Rajaram found that a diet rich in fish decreased serum triglyceride and increased HDL-cholesterol concentrations [5] . Consequently, adding oily fish to a daily diet decreased serum cholesterol and triglyceride concentrations, respectively, which affects CHD risk positively. Ramel observed that salmon consumption decreased diastolic blood pressure, similar to fish oil, and significantly more than lean fish. Among the most studied novel biomarkers are the inflammatory biomarkers and C-reactive protein (CRP) [6] . The use of novel biomarkers to increase standard risk algorithms has attracted increasing attention in recent years [7] . These biomarkers provide important prognostic information beyond that attainable with traditional cardiovascular risk factors in the setting of acute coronary syndrome [8] . Observational studies have consistently shown that higher plasma levels of CRP are linked with increased the risk of CHD and measurement of CRP has been suggested as a means of improving risk prediction [9] . Here, we systematically reviewed and meta-analysed available studies to evaluate the potential effects of fish consumption on vascular risk factors in randomised controlled trials (RCTs).
Methods
This systematic review was conducted according to The Cochrane [10] and the Centre for Reviews and Dissemination guidelines [11] and is reported according to PRISMA guidelines (Supplementary material: Table S1 ) [12] . The protocol has been registered with PROSPERO, the International Prospective Register of Systematic Reviews (Registration number CRD42016041288).
The search strategy for the identification of the studies is summarized in Figure 1 and we identified the evidence published until June 2017. We used three electronic databases, OVID MEDLINE, Scopus, and EMBASE, and these were searched from inception. The search strategy included the following terms: fish OR "oil-rich fish" OR salmon OR sardine OR mackerel AND trial OR intervention AND cardiovascular markers. The systematic review was restricted to articles published in English.
Two researchers (AA, JL) screened the titles and abstracts, selected the studies to be included in the review, and extracted the data. When screening the studies identified, the researchers decided whether the item was relevant or not, based on the title and abstract reading. If relevant, the referenced articles included in the item (review or meta-analysis) were passed to the list of potential articles to include in this review. When evaluating the clinical trials and RCTs, the researchers made an initial decision on the pertinence of the article and whether it should remain on the list based on the title and abstract reading, with the following inclusion and exclusion criteria:
• Inclusion criteria:
Clinical trials and RCTs, which directly assessed the effect of the intake of measured quantities of fish as a food on vascular risk factors, adult subjects >18 years of age, nutritional/dietary interventions and health-related outcomes.
• Exclusion criteria:
Articles written in languages other than English, subjects <18 years of age, noninterventional studies, non-nutritional dietary interventions and non-physical capability interventions.
Outcome measures
The following lipid biomarkers were selected as primary outcome measures (Triglycerides, total-, HDL-, LDL-and VLDL-cholesterol) and systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, insulin and Homeostasis-Model-Assessment-Insulin
Resistance (HOMA-IR), in addition to the inflammation markers, such as C-reactive protein (CRP), Interleukin-6 (IL-6) and Intercellular Adhesion Molecule (ICAM). Secondary outcomes were related to feasibility and acceptability aspects of these interventions.
Data extraction
The two reviewers extracted data independently and disagreements were resolved by consensus through discussion. The collected data included the author's last name, year of publication, country where the study was conducted, mean or range of age, mean of BMI, sample size, duration of follow-up, proportion of men and women, dose and frequency of consumption, retention rate, control, feasibility and acceptability of these interventions and baseline and after intervention plasma lipids levels. In studies reporting consumption of fish and supplements such as fish oils, only the data related with fish was extracted.
Statistical analysis
The Review Manager (RevMan Version 5.3 for Windows Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011) was used to pool and analyse results from the individual studies reviewed. Pooled results were reported as mean differences with 95% CI and with two-sided P-values. A random effects model accounting for inter-study variation was used, thereby minimizing potential bias due to methodological differences between studies. As suggested by Higgins and Green [10] , excessive weightings from "double counts"
originating from the control group were controlled by splitting the sample size of the shared group into approximately equal smaller groups for the comparisons; the means and standard deviations were left unchanged. The results are presented as forest plots. Statistical heterogeneity was evaluated using the I 2 statistic, which is reported as a percentage; the 95% CI for I 2 was calculated using Higgins and Thompson's method [13] . Where I 2 was >50%, the degree of heterogeneity was considered high. Evidence of publication bias was assessed by visual inspection of a funnel plot of effect size against the standard error (SE). Subgroup analysis was conducted according to sex, age, BMI, and health status of participants in the reviewed studies. Quality of studies was assessed using the Jadad score [14] which ranges from 0-5 focusing on randomization, blinding and description of dropout or withdrawals.
Because in the interventios studied it is difficult to blind participants to consuming fish, we considered the blinding of the outcome assessors as a quality criterion.
Results
The initial search identified 4,126 potentially relevant articles (2,390 from OVID MEDLINE, 1,736 from Scopus and 1,500 from EMBASE). The articles became 3,459 after duplicates were removed. After an initial screening, based on titles and abstracts, 20 articles remained.
After full-text assessment, 10 articles were excluded for various reasons and 7 additional articles were identified by other sources. Thus, the final set consisted of 17 articles reporting on 15 studies, which met our inclusion criteria and 13 studies provided data for the metaanalysis, while four studies did not report the effects of fish consumption on vascular risk factors (Supplementary material Figure S13 ).
Study inclusion and characteristics
The search identified seventeen studies published between 1990 and 2014 that met our inclusion criteria and these studies were designed with parallel (n=9) and cross-over (n=5) protocols (Table 1) . Four studies originated from the United Kingdom [15] [16] [17] [18] ; two from the USA [5, 19] , Norway [20, 21] The pooled study populations included 1,378 participants who were, on average, followed-up for 9 weeks (follow-up range from 4 to 24 weeks). The sample size in the studies ranged from 9 to 324. The mean ages of the samples in these studies ranged from 23 to 70 years. Seven studies included mixed sex samples, while six studies involved men only and two studies involved women only. Eight studies reported a mean BMI ≥25 kg/m 2 at baseline thus including a significant proportion of overweight and obese participants, while mean BMI was ≤25 in seven studies, and two studies did not report BMI (Supplementary material: Table   S1 ). The frequencies for consuming fish ranged from once a week to daily consumption, and the portion size of oily fish (most commonly, salmon) consumed on a given day ranged from 20 to 500 grams. All studies identified in this research required the fish to be consumed during the intervention. Seven studies involved healthy participants, three studies on overweight/obese, two studies involved patients with hyperlipidemia, one study on metabolic syndrome patients, one study on pregnant women and one study on CHD patients (Table 1) .
Various vascular risk factors (plasma lipids, inflammatory factors, and haemostasis) were evaluated in these studies. The overall percentage of subjects in RCTs who dropped out after randomization was small (7.5%).
Study quality and publication bias
The methodological quality and risk bias of the studies included in this review were assessed.
The included studies were characterised as good quality on Jadad's Score, with most studies scoring ≥3 out of 5 total score. The average retention rate for the 14 RCTs was 92.5% for all studies and the reason for the dropouts were often not relative to the interventions themselves. Therefore, the majority of the included studies satisfied the criteria of the quality assessment tool. Blinding of participants and researchers delivering the intervention was generally not feasible in these interventions. In addition, these included studies provided an adequate description of methods and randomization procedures; thus, no studies were excluded from analysis based on quality assessment.
Meta-analysis of vascular risk factors
The meta-analysis of fourteen studies/subgroups, including 1,128 individuals ( Subgroup analysis of these studies indicated that fish consumption was associated with reductions of triglycerides and HDL cholesterol, independent of sex, age, BMI or health status of participants ( Table 2) . 
Studies not in meta-analysis
In a 6-week intervention study [31] , significant reductions of serum triglycerides (−0.50 mmol/L), were reported in CHD patients consuming 700 g/week of salmon fed with a fish oil-based diet, thus having a greater content of n-3 fatty acids (30.2% weight) than in volunteers fed with salmon fillets containing intermediate (20.5% weight) and lower (11.7%) concentrations of n-3 PUFAs. In addition, another study reported that 500 g of mackerel per week for 4 weeks reduced platelet-monocyte aggregates by 35% in comparison with a control group receiving no dietary intervention [17] .
Discussion

Statement of principal findings
In the current meta-analysis of 14 published RCTs involving 1,378 adult participants, we found that consuming oily fish moderately (ranging from 20 g to 150 g per day) leads to a significant reduction in two important markers of cardiovascular risk, such as plasma triglycerides levels and an increase in HDL levels. We also found that fish consumption had no significant effect on total-, LDL-cholesterol, SBP, DBP, glucose, insulin, HOMA-IR, CRP, IL-6 and ICAM in both the short-to-medium term (4 to 12 months) and the longer term (>12 months). These findings support the beneficial effects of fish in reducing cardiovascular risk and highlight its important role as part of a healthy cardio-protective diet.
Strengths and limitations
To our knowledge, this report is the first systematic assessment through meta-analysis of the effectiveness of fish consumption on vascular risk factors among adult subjects >18 years of age within RCTs. We believe this review has several strengths. Firstly, this systematic review was conducted in adherence to standard guidelines and was based on three major electronic databases, namely, OVID MEDLINE, Scopus and EMBASE, which are considered to be the most relevant databases for this research topic. Secondly, there was a high retention rate (92.5%) among the selected studies for systematic review and meta-analysis (Table 1) , which means that the majority of participants were satisfied with the fish-related diet they were
given. In addition, this meta-analysis contains good quality studies reporting consistent results. Fourthly, the heterogeneity levels between the studies included in this meta-analysis were very low, in addition, the risk of publication bias was low, adding validity to the findings of this meta-analysis. Furthermore, the current meta-analysis only analysed data concerning fish consumption, thereby avoiding confounding factors, such as fish oil or other supplements as well as avoiding high heterogeneity. Sixthly, the amount of fish, which has been consumed in the studies, was provided to the participants to ensure that there was low variability in the serving size, as well as to reduce the dropout among the participants. Last, but not least, as most studies included in this analysis were performed in different populations (11 countries), the findings of this meta-analysis, therefore, are generalizable.
Conversely, this meta-analysis has some limitations. First of all, it is worth noting that studies published in languages other than English were not included, due to the lack of translation resources. In addition, given that most studies provided the fish to be consumed during the trial, it remains to be assessed whether people is able to increase fish consumption after receiving advice to do so. Follow-up in the trials was too short to investigate cardiovascular morbidity or mortality. Therefore, outcomes were limited to surrogate markers, such as cardiovascular risk factors.
Scientific analysis of findings
Research into the effectiveness of fish consumption on vascular risk factors is still limited. As far as we are aware, there is no other systematic review regarding the relationship between fish consumption and vascular risk factors. The current study is an addition to the literature in this topic.
The results of this systematic review suggest that the reduction of CVD mortality risk associated with the consumption of fish is likely to be related to the significant reductions in triglycerides and increases in HDL cholesterol. This systematic review also examined the effects of fish consumption on other CVD outcomes (the primary outcomes in this study, including inflammatory markers), and the results suggest there is no association between fish consumption and inflammatory markers.
However, Zampelas et al [38] found that fish consumption was independently associated with lower inflammatory markers levels (on average, 33% lower CRP, 33% lower IL-6 and 21%
lower TNF-alpha) among those healthy adults who consumed more than 300 g of fish per
week.
Implications for health
The Animal studies suggest that fish consumption may increase levels of HDL-cholesterol, not only through the mechanism involving n-3 fatty acids, but also possibly through the effects exerted by fish proteins on lipid metabolism [41] . Fish protein is rich in essential amino acids and are easily digestible. Depending on the composition of the diet and the quantity of proteins, fish protein has reportedly promoted lipid secretion and slow absorption and synthesis of lipids [42] .
Unanswered questions and future research
This work has focused on markers of CVD, therefore it remains to be answered if fish consumption improves overall global health. This study did not identify studies focusing on people over the age of 70 years old nor less than 18 years old. Therefore, future research should evaluate whether the health effects of fish consumption on vascular risk factors are relevant to people in these age groups. With an increasing prevalence of CVD, there is a need for larger and long-term RCTs of the effectiveness of fish consumption on vascular risk factors. Further ongoing studies with sufficient sample size, standardized dosing, and adequate follow-up duration are required to clarify the role of fish and seafood for the prevention of CVD.
Conclusion
This systematic review and meta-analysis included all known RCTs of the effectiveness of fish consumption on vascular risk factors, including triglycerides, cholesterol, blood pressure and inflammatory factors, which were evaluated by reviewing the available published intervention trials. Evidence from this systematic review shows that consuming oily fish (ranging from 20 g to 150 g per day) leads to a moderately significant reduction in plasma triglycerides levels and an increase in HDL levels. These findings suggest that fish consumption directly influences important markers of cardiovascular risk in humans.
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